Source: International Congress 2014 – Pulmonary hypertension in lung disease
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
G. Juan, J. Milara, J. L. Ortiz, J. Escriva, M. Ramon, E. Fernandez, J. Cortijo (Valencia, Spain). Sildenafil inhibit dose-dependently profibrotic and remodelling effects of TGFbeta1 on pulmonary arteries from patients with idiopathic pulmonary fibrosis (IPF). Eur Respir J 2014; 44: Suppl. 58, 2341

Member's Comments

Vern Rodriguez (Mountain View, United States of America) - 07.09.2014 20:09
Please send me a PDF copy of this poster. Verna@pneumrx.com Thank you.

Related content which might interest you: Sildenafil decreases the contractile response to serotonin (5HT) in pulmonary arteries from patients with idiopathic pulmonary fibrosis (IPF) and pulmonary hypertension (PH) Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Pulmonary hypertension in patients with idiopathic pulmonary fibrosis Source: Eur Respir Mon 2012; 57: 148-160 Year: 2012 Role of JAK2/STAT3 pathway in vascular function of pulmonary fibrosis patients Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015 Non-invasive haemodynamic measurement to detect treatment response in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Pulmonary hypertension in idiopathic pulmonary fibrosis Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis Year: 2010 Pulmonary hypertension in idiopathic pulmonary fibrosis: Utility of HRCT Source: International Congress 2014 – COPD and PAH related imaging Year: 2014 The contributing factors to mean pulmonary artery pressure in idiopathic pulmonary fibrosis Source: International Congress 2016 – Latest insights into chronic care Year: 2016 mir-126 contribute to angiogenesis defect in pulmonary arterial hypertension right ventricle failure Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 Inflammasome ASC-knock out attenuates the development of pulmonary hypertension caused by chronic alveolar hypoxia Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Muscle function and physical activity in patients with idiopathic pulmonary arterial hypertension (IPAH) Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Pulmonary vascular changes in COPD and idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2006 - Clinical physiology Year: 2006 Right ventricular REMODELING in idiopathic pulmonary fibrosis with or without pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: the right ventricle and its load Year: 2015 Comparison of current therapies against endothelin-induced growth in pulmonary smooth arterial muscle cells (PASMCs) derived from patients with pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Th17 inflammation and pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Specific pulmonary arterial hypertension therapy in COPD patients with severe pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Phosphodiesterase inhibitors as promising therapies for cigarette smoke-induced emphysema and pulmonary hypertension (PH) in mice Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 Pulmonary hypertension correction in patients with chronic obstructive pulmonary disease and essential hypertension Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Effects of riociguat in patients with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following pulmonary endarterectomy (PEA) Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 M2 macrophages derived from patients with idiopathic pulmonary arterial hypertension are susceptible for apelin-mediated suppression of pro-inflammatory cytokines Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 The flavonoid quercetin reverses monocrotaline-induced pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014